Date: 2013-01-18
Type of information: Licensing agreement
Compound: APN311
Company: Apeiron Biologics (Austria) Paladin Labs (Canada)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: APN311 is a monoclonal chimeric antibody (ch14.18/CHO) targeting the GD2 antigen on neuroblastoma cells.
Disease: neuroblastoma
Details: Apeiron Biologics has announced the closing of its first transaction in its ongoing initiative to out-license APN311, an antibody-based immunotherapy in development for the treatment of children with high-risk neuroblastoma. Paladin Labs, one of Canada's leading specialty pharmaceutical companies, entered into an exclusive licensing agreement with Apeiron, under the terms of which Paladin receives the exclusive rights to market and sell APN311 in Canada and Sub-Saharan Africa (including South Africa). Further details or financial terms of the transaction were not disclosed. APN311 is currently undergoing a randomized Phase III in Europe.
Financial terms:
Latest news:
